NASDAQ: SINTSintx Technologies Inc Stock
$2.98+0.09 (+3.11%)
Updated Mar 25, 2025
SINT Price
$2.98
Fair Value Price
N/A
Market Cap
$7.50M
52 Week Low
$2.01
52 Week High
$45.60
P/E
-0.2x
P/B
1.92x
P/S
0.9x
PEG
N/A
Dividend Yield
N/A
Revenue
$2.89M
Earnings
-$11.02M
Gross Margin
26.8%
Operating Margin
-380.85%
Profit Margin
-381.8%
Debt to Equity
1.42
Operating Cash Flow
-$9M
Beta
1.08
Next Earnings
May 12, 2025
Ex-Dividend
N/A
Next Dividend
N/A
SINT Overview
Sintx Technologies, Inc., an advanced materials company, engages in the research, development, and commercialization of medical devices manufactured with silicon nitride for biomedical, industrial, and antipathogenic applications primarily in the United States. The company provides solid and porous silicon nitride; silicon nitrite powder; and silicon nitride coating products, as well as silicon nitride composite materials and polyetherketoneketone. The company was formerly known as Amedica Corporation. Sintx Technologies, Inc. was incorporated in 1996 and is headquartered in Salt Lake City, Utah.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine SINT's potential to beat the market
- SINT doesn't meet the minimum data requirements for our proprietary Zen Ratings model. Learn more about Zen Ratings.
Zen Rating Component Grades
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Medical Device
Industry Rating
C
SINT
RankedUnranked of 108
RankedUnranked of 108
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $9.43 | A | |
| $24.11 | A | |
| $13.39 | A |
Be the first to know about important SINT news, forecast changes, insider trades & much more!
SINT News
Overview
Due Diligence Score
–
Industry Average (27)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how SINT scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
SINT is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
SINT is good value based on its book value relative to its share price (1.92x), compared to the US Medical Devices industry average (3.97x)
P/B vs Industry Valuation
SINT is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more SINT due diligence checks available for Premium users.
Valuation
SINT price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-0.2x
Industry
43.05x
Market
32.24x
SINT price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
1.92x
Industry
3.97x
SINT is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
SINT's financial health
Profit margin
Revenue
$542.0k
Net Income
-$1.7M
Profit Margin
-312.7%
SINT's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
SINT's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$9.4M
Liabilities
$5.5M
Debt to equity
1.42
SINT's short-term assets ($4.77M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
SINT's short-term assets ($4.77M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
SINT's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
SINT's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$1.1M
Investing
$10.0k
Financing
-$102.0k
SINT's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
SINT vs Medical Device Stocks
Sintx Technologies Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.